This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose.
Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.

Start Date01 Apr 2026

Sponsor / Collaborator

Duke University

[+1]

NCT07427251

/ Not yet recruitingPhase 4

Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People With Type 1 Diabetes

The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.
The primary endpoint is difference in the change in plasma glucose (PG) from exercise initiation to the nadir during exercise and through the 2-hour post-exercise period between the glucagon (GCN) and carbohydrate (CHO) visits.

Start Date01 Apr 2026

Sponsor / Collaborator

Steno Diabetes Center Copenhagen

CTRI/2025/11/097025

/ Not yet recruitingNot Applicable

Role of Glucagon during rapid sequence intubation (RSI) in elderly patients on beta blocker: A randomised controlled trial - NIL

Start Date15 Jan 2026

Sponsor / Collaborator

AIIMS Kalyani

100 Clinical Results associated with Glucagon

100 Translational Medicine associated with Glucagon

100 Patents (Medical) associated with Glucagon

7,833

Literatures (Medical) associated with Glucagon

01 Apr 2026·DEN open

Inhibitory Effect of Lidocaine on Duodenal Peristalsis During Endoscopic Retrograde Cholangiopancreatography: A Multicenter, Randomized Controlled Trial (With Video)

Article

Author: Kawana, Kenichi ; Uechi, Hiroki ; Nagase, Hajime ; Sekino, Yusuke ; Hosono, Kunihiro ; Kubota, Kensuke ; Yoneda, Masato ; Kuzuu, Kento ; Uchiyama, Shiori ; Suzuki, Masato ; Nakajima, Atsushi ; Kurita, Yusuke

ABSTRACT:

Objectives:

Conventional antispasmodics used during endoscopic retrograde cholangiopancreatography (ERCP), such as hyoscine butylbromide and glucagon, are often contraindicated in elderly patients with comorbidities. This trial aimed to assess the efficacy of lidocaine for inhibiting duodenal peristalsis during ERCP.

Methods:

This multicenter randomized controlled trial enrolled 40 elderly patients (aged 65–89 years) who were scheduled to undergo ERCP. Patients were randomly assigned to the lidocaine group or the control group using a computer‐generated sequence with stratification by age and sex. The lidocaine group ( n = 19) received 2% lidocaine jelly mixed with saline, while the control group ( n = 21) received a placebo jelly mixed with saline. The primary endpoint was inhibition of duodenal peristalsis. Secondary endpoints included the required time from drug spraying to cessation of duodenal peristalsis, stop duration time (DT) from cessation of peristalsis until peristalsis recovery, and adverse events.

Results:

Eighteen patients from the lidocaine group and 19 patients from the control group were analyzed for the primary outcome. The inhibition rate of duodenal peristalsis was significantly higher in the lidocaine group (94.4%) than in the control group (52.6%) ( p = 0.008). The required time was significantly shorter in the lidocaine group than in the control group ( p < 0.001). No significant difference was observed in the stop DT ( p = 0.862); no adverse events occurred in either group.

Conclusions:

In our limited cohort, lidocaine inhibited duodenal peristalsis during ERCP without adverse events, suggesting its potential as a safe and practical option (jRCT No. 031190059).

01 Feb 2026·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effectiveness of treatments for propranolol toxicity: a systematic review of current approaches and evidence

Review

Author: Inza ; Mujahid, Khizra ; Ahsan, Awais ; Aslam, Muhammad Arif ; Fatima, Anika ; Younas, Sadia ; Butt, Maham Anoosh ; Ahmed, Maham Maqsood ; Javaid, Hafiz Muhammad Ahmad ; Hu, Yafei

PURPOSE:

Propranolol, a non-selective beta-blocker characterized by high lipid solubility, is extensively prescribed for cardiovascular and central nervous system disorders. Nevertheless, it is frequently implicated in intentional overdoses due to its central nervous system penetration and membrane-stabilizing properties, often resulting in life-threatening bradycardia, hypotension, seizures, and cardiac arrest. This systematic review aimed to assess the efficacy of the current medical and mechanical interventions employed in the management of propranolol toxicity.

METHODS:

A comprehensive literature search was conducted using PubMed, EMBASE, CENTRAL, and Google Scholar for studies published between 1965 and March 18, 2025. Search terms included "propranolol toxicity," "glucagon," "high-dose insulin therapy," "lipid emulsion," "calcium," and "extracorporeal life support." Studies were included if they confirmed propranolol toxicity, evaluated at least one therapeutic intervention, and reported the clinical or hemodynamic outcomes. Expert opinions, narrative reviews, and letters to the editor were excluded from the analysis.

RESULTS:

A total of 92 studies were included, comprising observational studies, case series, detailed case reports, preclinical animal experiments, and animal control trials. Glucagon emerged as the most frequently utilized pharmacologic agent, followed by high-dose insulin euglycemic therapy (HDIET), intravenous lipid emulsion (ILE), inotropes, and calcium salts. Mechanical interventions such as extracorporeal life support (ECLS), pacing, and hemoperfusion have been reported in severe or refractory cases. The quality of evidence varied, with most studies limited by design heterogeneity, small sample sizes, and a lack of randomized controlled trials.

CONCLUSION:

Multiple interventions, including glucagon, HDIET, ILE, calcium, and ECLS, have demonstrated benefits in managing propranolol toxicity. However, owing to the low level of evidence and wide variability in patient presentations and treatment protocols, no single therapy exhibits universal efficacy. Individualized multimodal treatment remains essential, and high-quality clinical studies are necessary to establish standardized evidence-based protocols.

01 Feb 2026·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

Article

Author: James Goodman ; Fotini Kaloyirou ; Giovanni Di Stefano ; Lutz Jermutus ; Joseph Cheriyan ; Annette Hubsch ; Jo Helmy ; Carmel M. McEniery ; Ian B. Wilkinson ; Evangelia Vamvaka ; Navazh Jalaludeen ; Victoria E. Parker ; Peter Barker ; Philip Ambery

Aims:

Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination. The aim was to explore the acute haemodynamic effects of dual agonism at the GLP‐1 and glucagon receptor.

Methods:

Healthy male participants attended randomized, saline‐controlled intravenous infusion studies using glucagon (low, 25 ng/kg/min), glucagon (high, 50 ng/kg/min), exenatide (loading dose 50 ng/min for 30 min then 25 ng/min) and exenatide:glucagon co‐infusion for 120 min in Part A (glucagon dose‐comparison study) and 60 min in Part B (dual‐agonism study).

Results:

In Part A (n = 7, median age 21 years, interquartile range 21‐32 years), glucagon (high) increased heart rate by 11 beats per minute (bpm) (95% confidence interval [CI] 4‐17 bpm, P < .01). In Part B (n = 12, median age 24 years, interquartile range 22‐26 years), exenatide increased heart rate by 4 bpm (95% CI 2‐6 bpm, P < .001). Glucagon (low) increased heart rate by 4 bpm (95% CI 1‐7 bpm, P < .001). Co‐infusion of glucagon (low) and exenatide increased heart rate by 7 bpm (95% CI 4‐9 bpm, P < .001) and the rate pressure product by 793 mmHg*bpm (95% CI 460‐1127 mmHg*bpm, P < .001). There were no differences in cardiac output, blood pressure or heart rate variability.

Conclusions:

In healthy males, exenatide and glucagon co‐infusion acutely increases the rate pressure product, an indirect measure of cardiac work. This increase is driven by an increase in heart rate, rather than any change in systolic blood pressure.

News (Medical) associated with Glucagon

24 Feb 2026

·www.biospace.com

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent ® HFA Inhalation Aerosol. Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with Paragraph IV certification. This exclusivity period will begin on the first day that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is commercially launched. "We are excited to announce FDA approval of Ipratropium Bromide HFA Inhalation Aerosol, reinforcing the strength of our integrated R&D and manufacturing model and demonstrating our ability to deliver complex, high-value generics," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "We expect this launch to contribute meaningfully to our respiratory portfolio and to further strengthen our long-term growth strategy, capabilities and commitment to delivering impactful therapies to patients as we increase our efforts on the development of proprietary pipeline candidates." Ipratropium is an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. According to IQVIA, the U.S. sales for Atrovent ® HFA were approximately $112 million for the 12 months ended December 31, 2025. Amphastar plans to launch its Ipratropium Bromide HFA Inhalation Aerosol, previously referred to as AMP-007, early in the second quarter of 2026. Pipeline Information The Company currently has one ANDA and one biosimilar insulin filed with the FDA targeting products with a combined market size of over $1.7 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $1 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2025. The Company is developing multiple proprietary products with injectable and intranasal dosage forms. The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions. About Amphastar Pharmaceuticals, Inc. Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at . Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ® , BAQSIMI ® , Primatene MIST ® , REXTOVY ® , Amphadase ® , Ampsilog TM and Cortrosyn ® , are the property of Amphastar. Forward-Looking Statements All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI ® . You can locate these reports through our website at and on the SEC's website at . The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact Information: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 476-3416 SOURCE: Amphastar Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Drug Approval

28 Jan 2026

·endpoints.news

Halozyme buys drug delivery biotech Surf Bio; Sanofi backs Sensorion

Plus, news about Johnson & Johnson’s Darzalex Faspro, Altimmune, CalciMedica and Baseline Therapeutics: 🏄 Halozyme acquires Surf Bio for $300M upfront: Halozyme said Wednesday the deal centers around Surf’s “hyperconcentration technology,” which is designed to allow higher doses of drugs to be used in self-injectable formulations. Halozyme can pay another $100 million in milestones, bringing the total deal value to $400 million. — Max Gelman 💶 Sensorion raises €60M with Sanofi backing: Sanofi contributed €20 million (about $24 million) to the financing, which totaled $71.8 million. Sensorion said the cash will fund operations until the first half of 2027 and advance two of its experimental therapies. — Max Gelman 🟢 FDA approves Darzalex Faspro with new endpoint: Regulators said the Johnson & Johnson drug can now be used to treat newly diagnosed multiple myeloma patients who are ineligible to receive a stem cell transplant. It’s the first time the FDA has used minimal residual disease as an approvable endpoint, a move the agency announced last week. It’s the sixth overall approval for Darzalex Faspro, which is an injectable version of the blockbuster Darzalex franchise. — Max Gelman 💰 Altimmune’s $75M offering: The Maryland biotech sold 17 million shares to help fund the preparation of its proposed Phase 3 in MASH. The company is testing a glucagon/GLP-1 dual agonist called pemvidutide . — Kyle LaHucik 🛑 CalciMedica calls off mid-stage acute kidney injury trial : The company has stopped the KOURAGE study, testing its calcium release-activated calcium channel inhibitor Auxora, after an unspecified safety concern was found in a scheduled interim data review. The issue means the study’s design, particularly the patient enrollment criteria, needs to be reevaluated. No deaths were assessed as linked to the drug. — Elizabeth Cairns 🚀 Baseline Therapeutics emerges with GLP-1 for alcohol use disorder : The startup plans to start two Phase 3 trials of a weekly injection, designated BT-001, in the second quarter of this year. It also plans to test the drug in stimulant and opioid use disorders. — Elizabeth Cairns

Drug ApprovalPhase 3

27 Jan 2026

·ir.altimmune.com

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The offering is expected to close on or about January 29, 2026, subject to the satisfaction of customary closing conditions. Altimmune intends to use the net proceeds to fund preparation for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) as well as for working capital and general corporate purposes. Pemvidutide is a balanced glucagon/GLP-1 dual agonist and has the potential to be a highly differentiated therapy for patients with MASH, as demonstrated by the recently-announced Phase 2b 48-week topline data and the Breakthrough Therapy Designation from the U.S. FDA. The Company continues to focus on delivering meaningful impact for patients and long-term value for shareholders. Titan Partners, a division of American Capital Partners, is acting as the sole placement agent for the offering. The securities are being offered by Altimmune pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC), which was declared effective by the SEC on December 5, 2025. The offering is made only by means of a prospectus supplement, which will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the closing of Altimmune’s anticipated public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and statements regarding the timing, size and expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities, and Altimmune’s ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Altimmune’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Altimmune’s other filings with the SEC. Any forward-looking statements contained in this press release represent Altimmune’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Altimmune explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Savannah Valade Real Chemistry Altimmune@realchemistry.com Source: Altimmune, Inc

Phase 2Breakthrough Therapy

100 Deals associated with Glucagon

External Link

KEGG	Wiki	ATC	Drug Bank
-	Glucagon	H04AA01	DB00040

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	Canada	Eli Lilly Canada, Inc.	25 Sep 2019
Hypoglycemia	United States	Eli Lilly & Co.	14 Nov 1960

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	Japan	Eli Lilly & Co.	21 Feb 2018
Diabetes Mellitus, Type 1	Phase 3	Canada	Eli Lilly & Co.	01 Sep 2013
Common Cold	Phase 1	Canada	Eli Lilly & Co.	01 Mar 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04992312 (RescuiNGkids, CTgov)	Phase 1	Diabetes Mellitus, Type 1	7	glucagon	igkohkmisy = ydtnzvfwkr fcppjnouno (ketphhbygm, slrnoarjvk - pddbyjjdez) View more	-	23 May 2024
Baqsimi (ESPE2022)	Not Applicable	HbA1c	68	Baqsimi® 3 mg	rilsjgclxu(zwjkeireav) = 21% soenvvaduq (hvkfzvriej ) View more	Positive	15 Sep 2022
NCT03970772 (Pubmed \| Diabetes Care)	Not Applicable	Diabetes Mellitus, Type 1	17	Mini-Dose Glucagon	xgulnwajva(ryzfmiusfg) = jbhmrcpeep ntanomeyfc (rfoshyhumw ) View more	Positive	17 Feb 2022
NCT02078726 (CTgov)	Phase 4	Colonic Cancer	100	Glucagon (Glucagon)	qowsgaeagx = bzlxahqyny nydlworrpi (sryddorrgo, jpmwqhjrcu - gegukbmgpi) View more	-	20 Apr 2021
				Glucagon (Placebo)	qowsgaeagx = wsxvulgyai nydlworrpi (sryddorrgo, srhmfgehcb - bqgqfsbzty) View more
NCT03533179 (Pubmed \| J Am Heart Assoc)	Phase 4	-	10	Esmolol+Saline	fnisornkka(mrnxxvymif) = rotzclupnm afhmqactay (voxjbznpdu, 9.7 - 26.9) View more	-	03 Nov 2020
				Esmolol+Glucagon Bolus	fnisornkka(mrnxxvymif) = yairlqcfqq afhmqactay (voxjbznpdu, 9.7 - 26.9) View more
NCT03421379 \| NCT03339453 (EASD2020)	Not Applicable	Hypoglycemia	-	Nasal glucagon	iakfrujyfk(meuhgaqroo) = isebuzrqxv hovyniiiek (oobczdhpfe ) View more	Positive	24 Sep 2020
				Injectable glucagon	iakfrujyfk(meuhgaqroo) = fiulcrdiwc hovyniiiek (oobczdhpfe ) View more
NCT03421379 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus	75	Glucagon Nasal Powder	savpuaxbgd(ghpvodzipo) = jzazjgcnnf brljwiwhis (jmfoxilqfb )	Non-inferior	01 Jul 2020
				Glucagon Hydrochloride Solution	savpuaxbgd(ghpvodzipo) = mqttvzpflb brljwiwhis (jmfoxilqfb )
NCT02806960 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Diabetes Mellitus, Type 1	12	Nasal Glucagon (Treatment 1)	orvwledrkm(vsooltuelm) = nkoabhyhbw sxdnaojnpb (rkmknaeeun, fyaklkqgcs - drwgniovxc) View more	-	13 Dec 2019
				Nasal Glucagon (Treatment 2)	orvwledrkm(vsooltuelm) = aiwvjibmgl sxdnaojnpb (rkmknaeeun, kovrvkqxru - sxwtchegiw) View more
NCT02171130 (CTgov)	Phase 3	Hypoglycemia \| Diabetes Mellitus, Type 1	129	Nasal Glucagon	ovioqorjcw = ckrlhbpzek vobqcqtdcf (zmasoadsdm, jbmjpuvydz - dyyphncems) View more	-	15 Oct 2019
NCT02806973 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Diabetes Mellitus, Type 1	32	Glucagon (Nasal Glucagon Treatment 1)	lxjgqulxtg(izmgthrhdz) = cxlhbqczmr bzsmajjmlc (dzkbwdapro, 1850) View more	-	14 Oct 2019
				Glucagon (Nasal Glucagon - Treatment 2)	lxjgqulxtg(izmgthrhdz) = uchplucyoh bzsmajjmlc (dzkbwdapro, 1760) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis